pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TLXTelix Pharmaceuticals Ltd

$TLX
North Melbourne, AUupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
1
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(6)

pipeline depth6 products
Preclinical: 1Phase 1: 1Phase 2: 2Phase 3: 1Marketed: 1
1Preclinical1Phase 12Phase 21Phase 31Marketed
Marketed
ILLUCCIX
Phase 3
lutetium (177Lu) rosopatamab tetraxetan
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 2
TLX-250
Metastatic Renal Cell Carcinoma
Phase 2
iodofalan I 131
Recurrent Glioblastoma Multiforme (GBM)
Phase 1
TLX-090
Bone Metastasis
Preclinical
TLX-102
Malignant Glioma

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Telix Pharmaceuticals Ltd jobs →

News

  • Shionogi makes $2B rare disease play with IntraBio buy
    With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-te…
    biospace · 1mo ago
  • 3 steps for taking on Novartis in radiopharma: Curium up first
    To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
    biospace · 1mo ago
  • Novartis secures new radioligand in $900M deal as competition strengthens
    As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.
    fiercebiotech · 1mo ago
  • Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
    Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
    biospace · 2mo ago
  • Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
    Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
    biospace · 2mo ago
  • Telix and radioisotope maker ITM merge in deal worth up to $2.35B
    Telix Pharmaceuticals is buying German radioisotope manufacturer ITM Isotope Technologies Munich SE for $1.65 billion upfront, but some deal milestones hinge on a recently rejected drug. The merger…
    endpoints · 2mo ago
  • Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
    Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendoc…
    biospace · 2mo ago
  • Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
    Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network.
    fiercebiotech · 2mo ago
  • STAT+: Radiopharma companies merge after one receives surprise FDA rejection
    ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two leading companies in the burgeoning radiopharmaceuticals field, are merging.
    stat · 2mo ago
  • After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer
    The FDA has signed off on the first-ever glioma drug imaging diagnostic more than a year after it initially rejected the med.
    fiercebiotech · 2mo ago
view all news mentions →
identifiers
ticker
$TLX
SEC CIK
0002007191
country
AU
source
sec_tickers
top tags
Oncology5Prostate Cancer1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 32m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?